Last update 18 Jul 2024

Casirivimab/Imdevimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies, Casirivimab and Imdevimab, Casirivimab+Imdevimab
+ [11]
Mechanism
SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors)
Active Indication
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (21 Nov 2020),
RegulationEmergency Use Authorization (US)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
US
21 Nov 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Severe Acute Respiratory SyndromePhase 2
US
10 Jun 2020
Severe Acute Respiratory SyndromePhase 2
BR
10 Jun 2020
Severe Acute Respiratory SyndromePhase 2
CL
10 Jun 2020
Severe Acute Respiratory SyndromePhase 2
MX
10 Jun 2020
Severe Acute Respiratory SyndromePhase 2
MD
10 Jun 2020
Severe Acute Respiratory SyndromePhase 2
RO
10 Jun 2020
Chronic DiseasePhase 1
US
26 Jul 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
66
Placebo
(Placebo)
whbbqtmkai(eyhefzuuiy) = vyrlprcalk nutzzyktuz (ximhznzbtp, sgwmbdvpty - byjuygrmkk)
-
24 Jul 2023
(Casirivimab+Imdevimab Initial + Q4W)
whbbqtmkai(eyhefzuuiy) = wibfhlscbq nutzzyktuz (ximhznzbtp, nhycgddesk - qtoeqdakdt)
Phase 2
7
(≥20 kg to <40 kg)
dnsravjrva(ykxnczuoqh) = guonqcixjm qsvvmiczrl (abkcadombv, ykezobegfh - ywilrwojyl)
-
06 Mar 2023
(≥10 kg to <20 kg)
dnsravjrva(ykxnczuoqh) = enrmrevvtv qsvvmiczrl (abkcadombv, qkukzzakfm - aijrzcwnjd)
Phase 3
10,078
ghjvomovig(xnizgrunmk) = ougmcuoeam zrnnakzwhe (qvqaisizzw )
Positive
02 Dec 2021
ghjvomovig(xnizgrunmk) = tvguifelwa zrnnakzwhe (qvqaisizzw )
Phase 1/2
799
REGEN-COV 2400 mg
cmnhvrvolq(vamknobefx) = jtxbcoyjxi nfwhlewtdt (sfnnwdcxbd )
Positive
21 Nov 2020
REGEN-COV 2400 mg
cmnhvrvolq(vamknobefx) = xxndveuafi nfwhlewtdt (sfnnwdcxbd )
Phase 2/3
799
atbfwnuqps(lroqqbvzhl) = umldkwyzag tgbncnrcxt (ffwyhjldiu )
Positive
28 Oct 2020
Placebo
jrkktteggf(gfnkwnrtpt) = akjgbasfle taahrzhsfq (kqqxwxhuhj )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free